[{"innerBlocks":[],"name":"core\/freeform","postId":1572,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"Mount Sinai Health System is working with data diagnostic firm AllerGenis to develop technology to improve food allergy detection.

More than 30 million people in the United States and Europe have food allergies, with one in 13 children at risk for life-threatening anaphylaxis, which is a severe reaction.

Mount Sinai has licensed its proprietary epitope mapping platform to AllerGenis. Epitope mapping is the process of identifying the binding site of an antibody on a target antigen, which is a substance that induces an immune response in the body and is instrumental in development of this new level of diagnostics.

\u201cWe are pleased to partner with AllerGenis on a research discovery with the potential to alleviate highly detrimental allergic reactions in both children and adults,\u201d says Erik Lium, executive vice president of Mount Sinai Innovation Partners. \u201cThis technology exemplifies Mount Sinia\u2019s commitment to innovation and translational research.\u201d

Also See:<\/b> Pulmonary fibrosis organization creates registry for research<\/a>

AllerGenis will use the Mount Sinai platform to bring diagnostics to clinicians treating patients with food allergies. The first product being offered to clinicians is a peanut allergy assay available in the fall of 2019; that will be followed by assays for milk, eggs, shellfish and tree nuts. An assay is the presence of and amount of a substance.

The epitope platform of Mount Sinai subdivides protein allergens into smaller peptides, called epitopes, and measures the reactivity of a patient\u2019s antibody levels to the epitopes. Each patient has a unique reactivity signature.

\u201cAllerGenis\u2019 diagnostic technology using epitope mapping is expected to accurately diagnose patients with food allergies and also markedly decrease misdiagnosis,\u201d says Hugh Sampson, MD, director emeritus of the Elliot and Roslyn Jaffee Food Allergy Institute at Mount Sinai.

AllerGenis now is developing a database of human epitope signatures to make it easier for clinicians to assess and manage patients with food allergies.","saveContent":"Mount Sinai Health System is working with data diagnostic firm AllerGenis to develop technology to improve food allergy detection.

More than 30 million people in the United States and Europe have food allergies, with one in 13 children at risk for life-threatening anaphylaxis, which is a severe reaction.

Mount Sinai has licensed its proprietary epitope mapping platform to AllerGenis. Epitope mapping is the process of identifying the binding site of an antibody on a target antigen, which is a substance that induces an immune response in the body and is instrumental in development of this new level of diagnostics.

\u201cWe are pleased to partner with AllerGenis on a research discovery with the potential to alleviate highly detrimental allergic reactions in both children and adults,\u201d says Erik Lium, executive vice president of Mount Sinai Innovation Partners. \u201cThis technology exemplifies Mount Sinia\u2019s commitment to innovation and translational research.\u201d

Also See:<\/b> Pulmonary fibrosis organization creates registry for research<\/a>

AllerGenis will use the Mount Sinai platform to bring diagnostics to clinicians treating patients with food allergies. The first product being offered to clinicians is a peanut allergy assay available in the fall of 2019; that will be followed by assays for milk, eggs, shellfish and tree nuts. An assay is the presence of and amount of a substance.

The epitope platform of Mount Sinai subdivides protein allergens into smaller peptides, called epitopes, and measures the reactivity of a patient\u2019s antibody levels to the epitopes. Each patient has a unique reactivity signature.

\u201cAllerGenis\u2019 diagnostic technology using epitope mapping is expected to accurately diagnose patients with food allergies and also markedly decrease misdiagnosis,\u201d says Hugh Sampson, MD, director emeritus of the Elliot and Roslyn Jaffee Food Allergy Institute at Mount Sinai.

AllerGenis now is developing a database of human epitope signatures to make it easier for clinicians to assess and manage patients with food allergies.","order":0,"get_parent":{},"attributes":[],"attributesType":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"dynamicContent":""}]

Mount Sinai licenses mapping platform for food allergy detection

More for you